Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Lenvatinib

16f82514-1781-5cf8-8bd9-b956e84fd824 · FDA Approved · targets FLT1_VEGFR1, FLT4_VEGFR3, KDR_VEGFR2, RET

Lenvatinib

MeasuredReference

Lenvatinib targets RET, KDR_VEGFR2, FLT4_VEGFR3. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

RETKDR_VEGFR2FLT4_VEGFR3TNIKFLT1_VEGFR1

Top hallmarks

  • tumor promoting inflammation2.7k
  • evading apoptosis2.3k
  • proliferation2.3k

Top pathways disrupted

  • apical junction6.2k
  • pi3k akt mtor signaling6.0k
  • allograft rejection5.6k

Resistance landscape — Lenvatinib

MeasuredReference

10 known oncogenic variants exist on Lenvatinib's top targets — see detail for inhibition impact.

Open in new tab